<DOC>
	<DOCNO>NCT00712439</DOCNO>
	<brief_summary>The purpose study determine whether new Gabapentin tablet , safe effective treatment painful diabetic peripheral neuropathy .</brief_summary>
	<brief_title>Safety Efficacy Gabapentin Diabetic Peripheral Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>Men woman 18 year old diagnosis type 1 type 2 diabetes report symmetrical painful symptom distal extremity 15 year prior study whose symptom attributable sensorimotor diabetic peripheral neuropathy ( DPN ) . Patients childbearing potential must negative urine pregnancy test screening/randomization , must use medically acceptable method birth control . Patient pain score least 4 11point Likert numerical rating scale screen . Potential patient inform pain intensity eligibility criterion prior screen randomization . Patient mean baseline week pain intensity least 4 11point Likert scale end oneweek pretreatment period complete least 4 day diary entry baseline week . Patient stable regimen antidiabetes medication screen maintain study . Patient hemoglobin A1c ( HbA1c ) ≤11 % screening . Patient FPG ≤310 mg/dL screen . Patient must minimum washout great 5 time halflife drug several medication Patients currently treat gabapentin pregabalin screening may eligible study , must taper period wherein dose gabapentin reduce gradually period least 7 day plus 2day 3day washout gabapentin pregabalin , respectively , prior start Baseline Week . Patient must adequate eyesight complete question DiaryPro SitePro . If patient unable ( reason severe eye disease ) caregiver available complete task follow instruction patient , caregiver may train accomplish task Patients previously respond treatment DPN gabapentin dose ≥1200 mg/day pregabalin dos ≥300 mg/day . Patients previously experience doselimiting adverse effect prevent titration gabapentin effective dose . Patient hypersensitivity gabapentin . Patient nursing mother . Patient use injected anesthetic steroid within 30 day baseline . Patient certain condition could confound evaluation painful DPN , particular , amputation toe , nondiabetic neurologic disorder ( e.g . phantom limb pain ) , skin condition affect sensation painful limb . Patient skin condition area affect neuropathy could alter sensation . Patient immunocompromised state . Patient estimate creatinine clearance &lt; 60 ml/min calculate use Cockroft Gault method ( Appendix 3 ) . Patient malignancy within past 2 year basal cell carcinoma . Patient gastric reduction surgery . Patient severe chronic diarrhea , chronic constipation [ unless attribute drug wash ] , uncontrolled irritable bowel syndrome ( IBS ) unexplained weight loss . Patient abnormal chemistry hematology result deem investigator clinically significant . Patient history substance abuse within past year . Patient 1 visit emergency room hospital within previous 30 day due hypoglycemia . Patient history seizure ( except infantile febrile seizure ) risk seizure due head trauma . Patient history pernicious anemia , untreated hypothyroidism , chronic hepatitis B C , hepatitis within past 3 month , HIV infection . Patient serious medical condition , opinion Investigator would jeopardize safety patient affect validity study result . Continuing use concomitant medication exclude Inclusion Criterion 8 . Patient participate clinical trial investigational drug device within 30 day screen visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>DPN ,</keyword>
	<keyword>Diabetic</keyword>
	<keyword>Peripheral</keyword>
	<keyword>Neuropathy</keyword>
	<keyword>Painful</keyword>
</DOC>